新消息！路特斯繁花成全球充电最快电动车之一 10分钟补能310km

Sure, here is a news article about the Lotus Eletre becoming one of the fastest-charging electric vehicles in the world:

路特斯繁花成全球充电最快电动车之一 10分钟补能310km

上海讯 - 2024年3月5日，吉利旗下豪华电动汽车品牌路特斯宣布，其首款电动超级跑车Emeya（繁花）在充电速度方面取得了突破性进展。根据P3测试结果，Emeya仅需14分钟即可将电池电量从10%充至80%，成为当今世界上充电速度最快的电动车之一。

充电速度突破行业标准

在P3测试中，Emeya在10%至80%的电池电量状态下，达到了402千瓦的峰值充电功率和331千瓦的平均充电功率。这意味着，在10分钟内，Emeya可以为车主增加310公里的续航里程。

这一成绩得益于路特斯为Emeya开发的全新电池架构和冷却系统。该电池架构采用了直接冷却技术，使电池组能够在更短的时间内吸收更多的能量。此外，路特斯还为Emeya配备了高达450千瓦的超快直流快充充电桩，进一步缩短了充电时间。

为电动车主带来更便捷的体验

路特斯表示，Emeya的快速充电速度将为电动车主带来更便捷的体验。车主无需花费大量时间等待充电，即可轻松完成长途旅行。

路特斯积极布局新能源汽车市场

近年来，路特斯积极布局新能源汽车市场，推出了多款纯电动车型。Emeya是路特斯的首款电动超级跑车，也是路特斯进军高端新能源汽车市场的重要战略产品。

随着Emeya的上市，路特斯有望在新能源汽车市场取得进一步突破。

以下是一些可以参考的新闻来源：

• 路特斯繁花成全球充电最快电动车之一 10分钟补能310km
• 充电10分钟增500公里这家中企吓坏特斯拉
• 路特斯繁花成全球充电最快电动车之一，10分钟补能310km - 凤凰网

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.